###### Strengths and limitations of this study

TRACY (TRAvailleurs du CYcle) is a new and rare cohort of uranium fuel cycle workers.Almost 13 000 workers have been included from 1958 to 2006.Only 1% of workers were lost to follow-up.In France, individual causes of death are only available since 1968.Further work is ongoing to allow for the detailed investigation of uranium-related risk.

Introduction {#s1}
============

Ionising radiation is an established carcinogen[@R1] and its effects on cancer risk are reasonably well understood and quantified, at least at high doses (\>100 mGy) and dose rates (\>5 mGy/h).[@R2] By comparison, cancer risks associated with internal exposures resulting from the incorporation of radionuclides into the body are less well quantified.[@R3] This is a major issue for radiation protection since internal exposures are responsible for a large portion of the population\'s collective effective dose due to exposure to naturally occurring radionuclides, such as radon, as well as medical diagnostic and occupational sources of internal exposures.[@R1] In addition, there is growing interest in health effects other than cancer following exposure to low doses of ionising radiation (eg, diseases of the circulatory system[@R4]), notably following internal exposure.[@R5]

With the exception of studies on radon, relatively few recent epidemiological studies have directly quantified the health effects of internal contamination in populations chronically exposed to radionuclides.[@R6] As a result, the International Commission on Radiological Protection, which elaborates and periodically updates international radiation protection recommendations, had to estimate the radiation-related risks of internal exposure to radionuclides, such as uranium, by combining epidemiological evidence from external exposure situations with that from experimental studies on the biological effects of internal emitters.[@R10] It would be preferable to have direct epidemiological evidence regarding the effects of internal exposure to such radionuclides. There is, therefore, the need for further studies of populations exposed to internal emitters, to help assess the adequacy of current radiation protection standards with respect to internal exposure.[@R5]

In addition to its radiological toxicity, uranium, as a heavy metal, may exhibit chemical toxicity. This chemical toxicity has been demonstrated on the kidney and brain,[@R11] and might possibly extend to other organs. Therefore, even if models used to predict radiation-induced health effects from uranium exposure proved strictly adequate, additional data would be needed to characterise the total (ie, radiological plus chemical) health effects of uranium exposure in humans. This further justifies the need to directly quantify these effects in exposed populations.

Cohorts of workers involved in the uranium fuel cycle are of interest to study the risks associated with internal contamination by uranium because many workers have been regularly monitored for internal exposure via bioassay analyses.[@R5] However, few such cohorts have been set up.[@R12] A recent review concluded that, so far, studies based on these cohorts have not provided reliable evidence on the potential health risks associated with uranium exposure, notably because of insufficient statistical power.[@R19] Pooling existing large cohorts of uranium workers and setting up new ones is clearly needed to improve the knowledge of the health effects of uranium exposure.[@R20]

France has operated a complete nuclear fuel production cycle since the 1960s. The French cohort of workers employed in the nuclear fuel production cycle (TRACY, TRAvailleurs du CYcle) was set up to assess the risk of cancer and non-cancer mortality related to internal exposure to uranium. Pilot studies were successfully conducted in specific subsets of this large cohort.[@R21] [@R22] The reconstitution of exposure data in the entire TRACY cohort is underway.

The aim of the current investigation was to describe mortality among the uranium workers in this new large cohort, by comparison with the general population.

Material and methods {#s2}
====================

Study design {#s2a}
------------

TRACY is a retrospective cohort designed to study the mortality of workers involved in the French uranium fuel cycle. As will be detailed below, occupational data were collected from 2009 to 2013 and cover a period spanning from 1958 to 2006, whereas mortality data cover a period spanning from 1968 to 2008.

Study population {#s2b}
----------------

The companies included in this study cover different steps of the nuclear fuel production cycle in France ([figure 1](#BMJOPEN2015010316F1){ref-type="fig"}): purification of concentrated natural uranium, conversion to uranium hexafluoride, enrichment by gaseous diffusion, fuel manufacturing and other activities such as storage (depleted and reprocessed uranium), and decontamination (waste and effluents). Companies involved in uranium mining and milling are not included, nor are companies that are end users of the nuclear fuel (eg, those involved in electricity production). The companies included and their respective main activities are presented in [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 1. TRACY is complementary to the French uranium miners cohort[@R23] and to the French nuclear workers cohort, designed to study the association between external chronic exposure to radiation and mortality,[@R24] whereas the main focus of TRACY is internal contamination by uranium. The overlaps between TRACY and the French cohorts of uranium miners and nuclear workers include 158 and 5057 participants, respectively.
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![Simplified diagram describing the French uranium fuel cycle.](bmjopen2015010316f01){#BMJOPEN2015010316F1}

Workers included in the cohort had to be employed for at least 6 months as members of the permanent staff of selected companies between 1958 and 2006. Personal identifiers and work histories were provided by the administrative departments of each company, either on paper or electronic files. The files were computerised whenever needed, validated and merged. Transfers from one company to another were taken into account to avoid duplicate counts and accurately reconstruct time spent in the different companies included in the TRACY cohort where workers were employed. The detailed characterisation of workplaces and job titles is a long-term task for this large cohort and is still underway.

The date of start of employment was defined as the earliest one if several periods of employment were recorded. The date of end of employment, whatever the reason (retirement, resignation, dismissal, job transfer to a company not included in the study), was identified from the last recorded period of employment. For workers still employed on 31 December 2006, the end of employment was set to that date.

Follow-up, vital status and causes of death {#s2c}
-------------------------------------------

For each worker, follow-up of vital status began on the most recent date among the following: date of initial employment plus 6 months, or 1 January 1968. The lower bound of the follow-up period had to be set to that date since the national registry that provides causes of death information in France (CépiDC-Inserm) can deliver no individual data before 1968. Among the cohort members who began working before 1968, 53 had died or would have been lost to follow-up before 1968 and could not be included in the mortality study. The date of end of follow-up was defined as the earliest among the following: date of death, last information date (for workers lost to follow-up) and 31 December 2008. Workers\' vital status and the date of death for workers who died were obtained from the National Vital Status Registry (Répertoire National d\'Identication des Personnes Physiques) by file matching on name, surnames, gender, date and place of birth. To avoid erroneous linkages, only workers with one possible match with the registry were considered as identified. Causes of death coded according to the International Classification of Diseases (ICD, V.8 for period 1968--1978, V.9 for 1979--1999 and V.10 for period 2000--2008, see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 2) and corresponding labels were obtained by file matching on gender, date and place of birth and date and place of death with the French national mortality registry (CépiDC-Inserm). In case of multiple matches, no causes could be obtained for these workers.

Statistical analysis {#s2d}
--------------------

Mortality rates were compared with those in the French general population (also obtained from CépiDC-Inserm) by computing standardised mortality ratios (SMRs), therefore controlling for potential confounders: sex, age (categorised as follows: 15--19, 20--24,..., 80--84, ≥85 years) and calendar period (categorised as follows: 1968--1972, 1973--1977,..., 1998--2002, 2003--2008) as classically performed for such analyses.[@R25] Using the Poisson exact method, confidence intervals (95% CIs) were calculated.[@R26] This was performed for specific causes of death (eg, cancer of specific organs or tissues) or broader groupings of causes (eg, all cancers, all circulatory diseases, cancer sites potentially associated with smoking).[@R27] [Online supplementary appendix](#SM1){ref-type="supplementary-material"} table 2 provides the definition and corresponding ICD codes of all causes of death considered. For the primary analysis, SMRs were computed for men and women grouped together. The 'All causes' group included workers with non-identified causes of death. Results were reported only for causes of death with at least five cases observed across the whole cohort.

Supplementary analyses were conducted for broad groupings of causes of death (all causes, cancers, diseases of the circulatory system and respiratory diseases) to examine the evolution of SMRs according to time since hire (categorised as follows: \<25, 25--39, ≥40 years), time since end of employment (categorised as follows: \<10, 10--19, ≥20 years), total duration of employment (categorised as follows: \<10, 10--24, ≥25 years) and attained age (categorised as follows: \<50, 50--65, ≥66 years).[@R28] Further analyses were conducted to estimate SMRs among men and women separately. We also conducted supplementary analyses according to groupings of companies involved in the three main steps of the uranium cycle (conversion, enrichment by gaseous diffusion and manufacturing of oxide fuel), in two ways. First, we considered workers involved in only one grouping of companies covering a specific step (therefore not allowing for overlap between population subgroups, by excluding workers who got involved during their careers in several groupings of companies covering different steps) and second, considering workers involved in at least one of these grouping of companies (therefore allowing for overlap between the population groupings analysed). For conversion, we considered workers employed by Comurhex (Malvési and Pierrelatte plants). For enrichment, we considered a specific subcohort extract from the TRACY cohort with workers involved in both military and civil enrichment.[@R29] Workers employed by FBFC-CERCA (Romans sur Isère and Pierrelatte plants) constituted the oxide fuel manufacturing grouping.

All analyses were conducted using SAS software, V.9.2 (Cary, North Carolina, USA).

The protocol of this study was validated by the French Data Protection Authority (CNIL), agreement number DR-2012-611.

Results {#s3}
=======

The inclusion process (summarised in [online supplementary appendix](#SM1){ref-type="supplementary-material"} figure 1) started from a base of 21 143 potentially eligible workers. After removal of duplicates (3063 tuples) and exclusion of workers who did not match the eligibility criteria, 12 713 workers were confirmed to be eligible and included in the study. After further exclusion of one worker with identifiers not sufficient to match with national files (place of birth unknown) and of workers either dead or who would have been lost to follow-up before 1968, the mortality analysis was performed on 12 649 workers.

Workers excluded were permanent status workers who cumulated less than 6 months of employment (N=641), trainees (N=2561), short-term workers (N=2036) and others special contracts (military service, scientific advisor, N=129). Excluded workers cumulated an average duration of work of 0.50 years. Contractors were not mentioned in the employee personnel files and therefore could not be considered.

The main characteristics of the cohort are presented in [table 1](#BMJOPEN2015010316TB1){ref-type="table"}. Among the 12 649 workers included, 88% were males. The cohort cumulated 342 258 person-years of observation. The mean duration of follow-up was 27 years. The mean age at the end of the study was 60 years. The mean age at hire was 30 years and 49 years at the end of employment. The mean duration of employment was 19 years. At the end of the follow-up, 82% of workers were still alive, 17% were deceased and 1% were lost to follow-up. Underlying cause of death was identified for 99% of the 2130 deaths recorded.

###### 

Description of the TRACY cohort

                                     Men          Women      All                                  
  ---------------------------------- ------------ ---------- ------------ ---------- ------------ ----------
  All workers                        11 122       87.9       1527         12.1       12 649       100
  Person-years                       303 606      88.7       38 652       11.3       342 258      100
  Vital status on 31 December 2008                                                                
   Alive                             8992         80.9       1386         90.8       10 378       82.1
    Still employed                   3937         35.4       620          40,6       4557         36.0
   Deceased                          2028         18.2       102          6.7        2130         16.8
    With identified causes           2009         99.1       102          100        2111         16.7
   Lost to follow-up                 102          0.9        39           2.5        141          1.1
                                     **Median**   **Mean**   **Median**   **Mean**   **Median**   **Mean**
  Year of birth                      1943         1945       1949         1951       1944         1946
  Age at death                       67.8         66.4       60.9         62.2       67.5         66.2
  Age at hiring                      28.1         30.5       26.4         28.9       27.9         30.3
  Age at end of employment (All)     53.8         49.8       47.5         45.5       53.1         49.3
   Still employed                    49.0         47.5       47.3         46.0       48.7         47.3
   Not employed anymore              56.9         51.1       48.4         45.1       56.7         50.4
  Duration of employment in years    19.9         19.4       14.3         16.6       19.3         19.0
  Age at beginning of follow-up      31.2         33.2       29.0         31.1       31.0         32.9
  Age at end of follow-up            61.1         60.5       56.3         56.5       60.6         60.0
  Duration of follow-up in years     28.3         27.3       25.5         25.3       27.9         27.1

TRACY, TRAvailleurs du Cycle.

SMRs are presented in [table 2](#BMJOPEN2015010316TB2){ref-type="table"} for the whole cohort. A substantial mortality deficit was observed for all-cause mortality compared to expectation based on French national rates (SMR 0.65; 95% CI 0.62 to 0.68; n=2130).

###### 

SMRs in the TRACY cohort (1968--2008)\*

  Cause of death                                                       Observed number of deaths   SMR        95% CI
  -------------------------------------------------------------------- --------------------------- ---------- ------------------
  **All causes**                                                       **2130**                    **0.65**   **(0.62--0.68)**
  **Non-cancers diseases**                                             1013                        0.58       (0.55--0.62)
   Diseases of the circulatory system                                  540                         0.68       (0.62--0.74)
    Hypertensive diseases                                              15                          0.56       (0.31--0.93)
    Ischaemic heart diseases                                           212                         0.71       (0.62--0.81)
    Cerebrovascular diseases                                           130                         0.75       (0.63--0.90)
    Other and unspecified disorders of the circulatory system          183                         0.61       (0.52--0.71)
   Respiratory diseases                                                88                          0.51       (0.41--0.63)
   Diseases of the digestive system (other than cirrhosis)             48                          0.58       (0.43--0.77)
   Diseases of the genitourinary system                                23                          0.70       (0.44--1.05)
    Renal diseases                                                     17                          0.66       (0.39--1.06)
   Other non-cancers diseases                                                                                 
    Non-malignant tumours of central nervous system and sense organs   10                          0.77       (0.37--1.42)
    Endocrine, nutritional and metabolic diseases                      47                          0.67       (0.49--0.89)
    Diseases of the blood and blood-forming organs                     7                           0.63       (0.25--1.30)
    Cirrhosis, psychosis and other diseases due--alcohol               48                          0.27       (0.20--0.35)
    Non-tumoural diseases of central nervous system and sense organs   68                          0.83       (0.64--1.05)
    Diseases of the skin                                               5                           1.14       (0.37--2.67)
    Diseases of the musculoskeletal system and connective tissue       8                           0.74       (0.32--1.46)
    Other                                                              121                         0.43       (0.35--0.51)
  **All cancers**                                                      **912**                     **0.76**   **(0.71--0.81)**
  **Smoking-related cancers**                                          495                         0.68       (0.62--0.75)
    Mouth                                                              13                          0.46       (0.25--0.79)
    Pharynx                                                            28                          0.57       (0.38--0.82)
    Oesophagus                                                         33                          0.52       (0.36--0.73)
    Stomach                                                            29                          0.64       (0.43--0.92)
    Liver                                                              31                          0.65       (0.44--0.92)
    Pancreas                                                           53                          1.05       (0.79--1.38)
    Nasal cavity, sinus and middle ear                                 5                           0.24       (0.08--0.57)
    Larynx                                                             20                          0.49       (0.30--0.75)
    Lung                                                               217                         0.73       (0.64--0.83)
    Bladder                                                            26                          0.69       (0.45--1.01)
    Kidney                                                             24                          0.84       (0.54--1.24)
  **Non-smoking-related cancers**                                      358                         0.87       (0.79--0.97)
    Colon                                                              60                          0.78       (0.60--1.01)
    Rectum                                                             26                          0.87       (0.57--1.28)
    Gallbladder and bile ducts                                         7                           0.98       (0.39--2.01)
    Pleura                                                             17                          2.04       (1.19--3.27)
    Melanoma                                                           15                          1.60       (0.90--2.64)
    Breast                                                             20                          1.32       (0.81--2.04)
    Prostate                                                           71                          0.94       (0.74--1.19)
    Brain and central nervous system                                   32                          1.36       (0.93--1.91)
    Other non-smoking-related cancers                                  106                         0.69       (0.57--0.84)
  **Haematological and lymphatic malignancies**                        74                          0.96       (0.75--1.20)
    Leukaemia                                                          33                          1.00       (0.69--1.40)
     Lymphocytic leukaemia                                             12                          1.38       (0.71--2.42)
      Chronic lymphocytic leukaemia (CLL)                              8                           1.28       (0.55--2.52)
    Myeloid leukaemia                                                  15                          1.06       (0.59--1.74)
      Acute myeloid leukaemia                                          10                          1.22       (0.58--2.24)
    Other leukaemia                                                    6                           0.59       (0.22--1.28)
    Leukaemia without CLL                                              25                          0.93       (0.60--1.38)
    Multiple myeloma                                                   18                          1.29       (0.77--2.05)
    Non-Hodgkin\'s lymphoma                                            23                          0.86       (0.55--1.30)
  **External causes**                                                  186                         0.54       (0.46--0.62)
    Suicides                                                           77                          0.66       (0.52--0.82)
    Accidents                                                          98                          0.47       (0.39--0.58)
    Other external causes                                              11                          0.49       (0.24--0.87)

\*For causes of deaths with at least 5 cases observed.

SMRs, standardised mortality ratios; TRACY, TRAvailleurs du CYcle.

There was a substantial deficit in mortality for most major categories of non-malignant diseases. All non-cancer mortality was in 42% deficit (SMR 0.58; 95% CI 0.55 to 0.62, n=1012). There were substantial deficits in deaths due to non-malignant respiratory diseases (SMR 0.51; 95% CI 0.41 to 0.63, n=88), circulatory diseases (SMR 0.68; 95% CI 0.62 to 0.74, n=540), non-malignant renal diseases (SMR 0.66; 95% CI 0.39 to 1.06, n=17) and external causes of death including suicides and accidents (SMR 0.54; 95% CI 0.46 to 0.62, n=186).

For deaths due to all malignant diseases grouped together, there was also a deficit in the entire cohort although less pronounced than for most non-malignant categories of cause of death. Overall, cancer mortality was in 24% deficit (SMR 0.76; 95% CI 0.71 to 0.81, n=912). However, a twofold excess was observed for pleural mesothelioma (SMR 2.04; 95% CI 1.19 to 3.27; n=17) and non-significant excesses were observed for other cancers: pancreas (SMR 1.05; 95% CI 0.79 to 1.38, n=53), skin melanoma (SMR 1.60; 95% CI 0.90 to 2.64, n=15), breast (all observed cases being among women, see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 3; SMR 1.53; 95% CI 0.94 to 2.37; n=20), brain and central nervous system (SMR 1.36; 95% CI 0.93 to 1.91, n=32), lymphocytic (SMR 1.38; 95% CI 0.71 to 2.42, n=12) and myeloid (SMR 1.06; 95% CI 0.59 to 1.74, n=15) leukaemia and multiple myeloma (SMR 1.29; 95% CI 0.77 to 2.05, n=18). In contrast, there was a substantial deficit in deaths due to smoking-related cancers (SMR 0.68; 95% CI 0.62 to 0.75, n=495).

SMRs for cancer diseases tended to increase with time since hire, time since end of employment and attained age ([table 3](#BMJOPEN2015010316TB3){ref-type="table"}). Twenty years after the end of employment, the risk of cancer mortality is not significantly different from that in the general population, whereas it remains significantly lower for circulatory and respiratory diseases. No clear trend was observed according to the duration of employment for mortality from all causes and from circulatory diseases. However, there was evidence of a decreasing trend along with duration of employment for mortality from cancer and respiratory diseases. For all broad groupings of causes of death, the lowest SMRs were observed in workers with the longest duration of employment ([table 3](#BMJOPEN2015010316TB3){ref-type="table"}).

###### 

SMRs and 95% CI in the TRACY cohort (1968--2008), by time since hire, time since end of employment, duration of employment and age reached, for broad groupings of causes of death

  Time since hire                                                                                 
  ---------------------- ----- ------ ---------------- ----- ------ ---------------- ----- ------ ----------------
  All causes             633   0.54   (0.50 to 0.58)   967   0.70   (0.66 to 0.75)   530   0.73   (0.66 to 0.79)
  All cancers            242   0.64   (0.57 to 0.73)   457   0.81   (0.74 to 0.89)   213   0.82   (0.71 to 0.93)
  Circulatory diseases   160   0.67   (0.57 to 0.79)   235   0.66   (0.58 to 0.75)   145   0.71   (0.60 to 0.83)
  Respiratory diseases   14    0.33   (0.18 to 0.55)   48    0.61   (0.45 to 0.81)   26    0.50   (0.33 to 0.73)

  Time since end of employment                                                                            
  ------------------------------ ----- ------ ---------------- ----- ------ ---------------- ----- ------ ----------------
  All causes                     945   0.56   (0.52 to 0.59)   591   0.74   (0.68 to 0.80)   594   0.75   (0.70 to 0.82)
  All cancers                    430   0.68   (0.62 to 0.75)   243   0.81   (0.71 to 0.92)   239   0.89   (0.79 to 1.02)
  Circulatory diseases           217   0.62   (0.54 to 0.71)   162   0.72   (0.61 to 0.84)   161   0.72   (0.61 to 0.84)
  Respiratory diseases           16    0.25   (0.14 to 0.41)   39    0.75   (0.53 to 1.02)   33    0.58   (0.40 to 0.81)

  Duration of employment                                                                             
  ------------------------ ----- ------ ---------------- ------ ------ ---------------- ----- ------ ----------------
  All causes               575   0.66   (0.61 to 0.71)   1073   0.67   (0.63 to 0.71)   482   0.60   (0.55 to 0.66)
  All cancers              243   0.82   (0.72 to 0.93)   426    0.78   (0.70 to 0.85)   243   0.69   (0.61 to 0.78)
  Circulatory diseases     126   0.66   (0.55 to 0.79)   314    0.73   (0.65 to 0.82)   100   0.56   (0.45 to 0.68)
  Respiratory diseases     25    0.62   (0.40 to 0.92)   48     0.50   (0.37 to 0.67)   15    0.40   (0.22 to 0.66)

  Attained age                                                                                     
  ---------------------- ----- ------ ---------------- ----- ------ ---------------- ------ ------ ----------------
  All causes             269   0.50   (0.44 to 0.56)   662   0.56   (0.52 to 0.61)   1199   0.77   (0.72 to 0.81)
  All cancers            78    0.60   (0.48 to 0.75)   358   0.70   (0.63 to 0.77)   476    0.86   (0.78 to 0.94)
  Circulatory diseases   52    0.67   (0.50 to 0.87)   147   0.59   (0.50 to 0.69)   341    0.73   (0.65 to 0.81)
  Respiratory diseases   5     0.38   (0.12 to 0.88)   13    0.29   (0.16 to 0.50)   70     0.61   (0.48 to 0.77)

SMRs, standardised mortality ratios; TRACY, TRAvailleurs du CYcle.

Significant deficits in all-cause and non-cancer mortality were observed for both genders (see [online supplementary appendix](#SM1){ref-type="supplementary-material"} tables 3 and 4). In women, non-significant excesses of cancer mortality were observed. However, CIs were very wide due to the lower number of women (and, therefore, of deaths observed in these women) in the cohort (see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 3). In men, a significant deficit in mortality from all cancers was also observed and results were overall comparable to those in the entire cohort (see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 4).

For all groupings of causes of death considered, we observed no difference in mortality patterns according to groupings of companies involved in the main three steps of the cycle, regardless of the way the groupings were defined (see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 5).

Discussion {#s4}
==========

This is the first mortality study conducted in this new cohort of uranium cycle workers, which is one of the largest of its kind. A healthy worker effect (HWE) is observed. It is especially strong for major groups of non-cancer diseases, including circulatory and non-cancer respiratory diseases. For all cancers grouped together, a healthy worker effect is also observed overall, but is less marked than for non-cancer diseases. No deficit in cancer mortality is observed in workers 20 years or older after the end of employment, or in women. A significant excess of malignant pleural mesothelioma is observed and non-significant excesses are observed for a few other specific cancer sites.

Mortality profile {#s4a}
-----------------

The HWE is often observed in occupational cohorts, including nuclear worker cohorts.[@R24] [@R25] [@R28] It partly results from the selection of healthier people at hiring (referred to as the 'healthy hire effect',[@R28] which tends to shrink with time since hire) and from other selection effects making the healthiest individuals more likely to be retained in the workforce than individuals with poorer health (referred to as the 'healthy survivor effect'[@R28] and reflected by the fact that workers with the longest duration of employment exhibit the lowest SMRs). The regular health surveillance provided by occupational medicine services as well as other factors such as work-related physical activity are also suspected to contribute to the healthy survivor effect. As time since the end of employment goes by, the mortality profile of workers tends to reach that of the general population. These patterns were observed in the TRACY cohort, in agreement with previous literature.[@R24] [@R25] [@R28] Methods have been proposed to calculate adjusted SMRs as a complement to the traditional SMR which may facilitate interpretation of findings in spite of comparability issues due to the HWE; a recent example of such an approach draws on methods developed for the use of negative control outcomes for bias reduction.[@R30] Such methods have not been applied in the current paper, however, since it is difficult to define a relevant negative control outcome for a population of workers exposed to uranium. In spite of the aforementioned limitations resulting from the HWE, comparisons of mortality profiles of occupational cohorts with those of general populations have been considered to be a useful approach and, therefore, have been widely used in occupational epidemiology.[@R18] [@R25] [@R31] [@R32]

Importantly, the observed HWE does not mean that no case attributable to uranium or to other sources of radiation occurred in the TRACY cohort. The present analysis provides a simple but informative picture of the general level of risk in this cohort of workers of the uranium fuel cycle, through a comparison with the general population. The risk in the cohort is not only influenced by uranium and other radiation exposures but also by the levels of exposure to other risk factors. For instance, the SMR for the grouping of cancer sites that may be caused by smoking[@R27] is low in the TRACY cohort. This suggests a lower level of exposure to smoking in this cohort than in the general population.

Conversely, we observed an excess of pleural mesothelioma. We acknowledge that the diagnosis and ascertainment of mesothelioma on death certificates has been problematic until at least the early 1990s.[@R33] This limitation applied both to the TRACY cohort and to the comparison group, the French general population.[@R34] The ascertainment of mesothelioma improved with the introduction of ICD10,[@R35] which was used since year 2000 for French death certificates. Excesses of pleural mesothelioma were also reported in most other nuclear worker cohort studies.[@R36] An excess risk was also observed in the French cohort of nuclear workers, designed to study the effects of external radiation exposure (based on 36 deaths),[@R37] but it has to be noted that these two results are not independent, due to partial overlap of the two cohorts, concerning workers from AREVA NC and CEA Pierrelatte plant (10 deaths in common, among 5057 workers included in both cohorts). Evidence for an association between exposure to ionising radiation and pleural mesothelioma is weak, however,[@R36] and, to the best of our knowledge, no association between uranium exposure and mesothelioma has ever been reported. By contrast, asbestos exposure is a strong risk factor for this disease, and has been known to occur in companies included in TRACY,[@R38] as well as in other companies in which some workers were employed before joining the nuclear fuel industry. This might contribute to the excess of malignant pleural mesothelioma observed in this cohort.

Non-significant excesses were observed for a few cancer sites in TRACY. For pancreas cancer, non-significantly positive SMRs were also observed in several other cohorts of uranium workers (including uranium millers)[@R14] [@R17] [@R39] [@R40] but not in all[@R15] [@R18] [@R31] [@R32] [@R41] (see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 6).

For all leukaemias grouped together, patterns are not consistent across cohorts either. A proper comparison by leukaemia subtype is hampered by the inhomogeneous sets of subtypes for which results were reported in available studies. However, non-significant excesses of multiple myeloma[@R17] [@R39] [@R42] or myeloma[@R32] were reported in most cohorts that evaluated this outcome (see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 6).

Non-significant excesses of cancers of the brain and central nervous system were reported in most cohorts of uranium workers.[@R14] [@R32] [@R39] [@R43] Although no single study detected a significant excess of brain cancer, the consistent pattern of non-significant excesses across cohorts for this outcome deserves further investigation (see [online supplementary appendix](#SM1){ref-type="supplementary-material"} table 6). Animal studies have shown that the brain is a target organ for uranium effects,[@R44] although, to the best of our knowledge, no animal study has specifically focused on brain or central nervous system cancers.

Only one other cohort of uranium fuel cycle workers reported a non-significant excess of skin cancer so far.[@R14] Only three studies reported non-significant excesses of breast cancer[@R14] [@R15] [@R18] and in two of them, the excess was only observed in women monitored for internal contamination.[@R15] [@R18]

Strengths and limitations {#s4b}
-------------------------

The TRACY cohort has major strengths, such as its large size and excellent quality of follow-up. It is one of the rare cohorts of uranium fuel cycle workers in the world. However, the present study also has some limitations. No individual data on causes of death were available before 1968 due to the late introduction of the French mortality registry. This limitation applies to all epidemiological studies in France. Uranium-related activities began as early as 1959 in some companies included in TRACY. However, the gap in temporal overlap before year 1968 could not hamper the detection of potential excess of diseases occurring after a long latency time following occupational exposure (eg, solid cancers are usually considered to occur after 10 or more years following radiation exposure). Similarly, the fact that occupational data have not been collected after year 2006 so far, although the mortality analysis covered the period 1968--2008, is unlikely to generate a substantial impact on the analysis of diseases with long latency times. However, the possible impact of the aforementioned lack of temporal overlap is less clear for diseases with shorter latency times, such as leukaemia. In addition, although the use of mortality data is very informative, it does not allow capturing the full range of possible health effects of uranium exposure, for instance, cognitive, reproductive effects or kidney damage.[@R11] More generally, it does not adequately capture the incidence of diseases that are rarely fatal.

The criteria for inclusion into the TRACY cohort guarantees that all permanent staff workers potentially exposed to uranium as part of the upstream steps of the French nuclear fuel cycle (except miners and millers) are included. However, it is clear that some workers not exposed to uranium are also included in the cohort. Having these workers in the cohort will be useful to constitute an internal reference group, when associations between uranium exposure and mortality will be studied. However, further work is still needed (especially a detailed reconstruction of bioassay record histories) before being able to separate all workers exposed from those non-exposed to uranium in the entire TRACY cohort. Complex changes in industrial processes combined with changes in individual job histories make it a long-term task.

However, as a preliminary approach, we explored the hypothesis of different health effects according to different parts of the uranium cycle, by conducting a first analysis by groupings of companies involved in the three main steps of the uranium cycle (conversion, enrichment and fuel manufacturing). We failed to demonstrate potential differences, possibly because of the lack of statistical power and inclusion of non-exposed workers in each group.

Perspectives {#s4c}
------------

The reconstruction of the multiple exposures of the workers in the TRACY cohort represents a necessary effort to assess risks according to different levels of exposure to uranium, while taking into account other sources of radiation (external exposure to X-ray and gamma rays, and internal contamination with radionuclides such as, for instance, uranium decay products, plutonium and tritium) and other potential risk factors, including carcinogenic, mutagenic or toxic to reproduction chemicals, heat, noise and shift work. Uranium exposure is being reconstructed by a dual approach combining individual monitoring data[@R47] and specific job-exposure matrices.[@R38] Job exposure matrices allow estimating exposures not covered by any individual monitoring and document uranium compounds present at each job. This detailed exposure reconstruction will allow us to distinguish more finely the different steps of the uranium fuel cycle and therefore better characterise the physicochemical characteristics of the different uranium compounds (in term of solubility and isotopy) to which workers were exposed.

The calculation of uranium concentrations in the target organs of uranium (eg, lungs, kidneys, bones and brain, among others) but also of resulting absorbed radiation doses to these same organs, will help in disentangling chemical from radiation effects of uranium exposure. This specific investigation will be possible since separate populations of workers have been exposed to uranium of different isotopic compositions, which show contrasted specific activity (eg, 0.33 μCi/g for depleted uranium, 0.68 μCi/g for natural uranium and up to 50 μCi/g for enriched uranium). Since depleted uranium has a very low specific activity, an estimate of the relationship between depleted uranium concentrations in organs and health risks will almost purely assess the potential chemical toxicity of uranium. Beside this, workers exposed to a same level of uranium concentration in organs will receive different internal radiation dose from this nuclide, depending on whether they were exposed to depleted, natural or enriched uranium (again, because of their varying specific activities). Comparing risks in workers exposed to uranium of different isotopic compositions will therefore provide an opportunity to isolate and quantify the radiological component of uranium toxicity. Last, information on risk factors such as tobacco smoking and various clinical parameters (body mass index, blood pressure, lipid profile, etc) is being collected from the occupational health services,[@R48] which will allow controlling for their potential confounding effects in future analyses.

The TRACY cohort is still young, with an average age of 60 years, and only 17% of workers were deceased at the end of follow-up. The statistical power available to study rare or specific diseases (eg, specific cancer sites) will remain limited in this cohort as well as in other cohorts of nuclear fuel cycle workers, unless large excesses actually occur (as was observed in TRACY, for pleural mesothelioma). Extended follow-up and pooled analyses of these cohorts, including TRACY, are needed to produce more statistically precise estimates, which will allow drawing more robust conclusions on possible excess for these diseases and their association with uranium exposure. A pooling of TRACY with other cohorts of uranium workers and miners in Europe is planned, according to harmonised methodologies defined as part of the European project CURE.[@R20] In the future, this approach could be extended to cohorts outside Europe.

Conclusion {#s5}
==========

This first mortality study of the TRACY cohort of French uranium cycle workers has shown a substantial mortality deficit for all broad groupings of causes of death and most of the pathologies studied. However, a significant excess of malignant pleural mesothelioma was also observed and non-significant excesses were observed for a few specific cancer sites. To go further in the investigation of uranium-related risks in this new cohort, collection of individual information on internal uranium exposure as well as other risk factors is underway.

Finally, through the pooling of TRACY with other cohorts of uranium workers, the TRACY cohort will help to improve the knowledge of the health effects of uranium exposure and more generally of internal contaminations by radionuclides, in support of radiation protection research and practice.
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